Insider Selling: uniQure (NASDAQ:QURE) CEO Sells 164,429 Shares of Stock

uniQure N.V. (NASDAQ:QURE) CEO Matthew Kapusta sold 164,429 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $44.32, for a total value of $7,287,493.28. Following the transaction, the chief executive officer owned 558,810 shares in the company, valued at approximately $24,766,459.20. This trade represents a 22.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Stock Performance

QURE stock opened at $46.29 on Monday. The firm has a market cap of $2.92 billion, a PE ratio of -13.30 and a beta of 0.98. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. The business has a 50 day moving average of $24.74 and a 200-day moving average of $22.17. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The firm had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. As a group, sell-side analysts expect that uniQure N.V. will post -3.64 earnings per share for the current year.

Institutional Trading of uniQure

Several institutional investors have recently bought and sold shares of QURE. Militia Capital Management LLC purchased a new position in shares of uniQure in the first quarter worth $1,540,000. Flax Pond Capital LLC boosted its position in shares of uniQure by 3.8% during the first quarter. Flax Pond Capital LLC now owns 152,031 shares of the biotechnology company’s stock worth $2,486,000 after acquiring an additional 5,533 shares during the last quarter. Stempoint Capital LP raised its holdings in shares of uniQure by 79.5% during the 1st quarter. Stempoint Capital LP now owns 78,066 shares of the biotechnology company’s stock worth $1,276,000 after acquiring an additional 34,581 shares in the last quarter. Irenic Capital Management LP bought a new position in shares of uniQure in the 1st quarter valued at about $1,635,000. Finally, Readystate Asset Management LP boosted its stake in uniQure by 39.6% during the first quarter. Readystate Asset Management LP now owns 504,702 shares of the biotechnology company’s stock worth $8,252,000 after buying an additional 143,142 shares during the period. 78.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on QURE. Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. The Goldman Sachs Group upped their price objective on shares of uniQure from $14.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday. Royal Bank Of Canada raised their price target on uniQure from $35.00 to $65.00 and gave the company an “outperform” rating in a research report on Thursday. TD Cowen reaffirmed a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Finally, Cantor Fitzgerald upgraded uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research report on Wednesday, June 17th. Twelve analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $58.92.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.